Karim Aouam

Prof. Dr. Karim Aouam


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2019 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
NFNajah Ben Fadhel
Najah Ben Fadhel
ACAmel Chaabane
Amel Chaabane
HAHelmi Ammar
Helmi Ammar
HRHaifa Ben Romdhane
Haifa Ben Romdhane
YSYosra Soua
Yosra Soua
KAKarim Aouam
Karim Aouam

1 May 2007 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
KAKarim Aouam
Karim Aouam
ACA. Chaabane
A. Chaabane
CLC. Loussaïef
C. Loussaïef
FRF. Ben Romdhane
F. Ben Romdhane
NBN.-A. Boughattas
N.-A. Boughattas
MCM. Chakroun
M. Chakroun

30 November 2015 in Pharmacogenomics
Verified
Journal Article
Closed access
KAKarim Aouam
Karim Aouam
AKAbdessalem Kolsi
Abdessalem Kolsi
EKEmna Kerkeni
Emna Kerkeni
NFNadia Ben Fredj
Nadia Ben Fredj
ACAmel Chaabane
Amel Chaabane
NBNaceur Boughattas
Naceur Boughattas
Aim: The present study investigated in Tunisian renal transplant patients, genetic polymorphisms of CYP3A4 -392A>G and CYP3A5 6986A>G and their influence on tacrolimus (Tac) pharmacokinetics during early and late post-transplant (PT) phases and established customized ranges of Tac doses matching the C0 target levels according to CYP3A4 and CYP3A5 genotype combination and the PT phase. Patients & methods: We included adult Tunisian patients having received Tac for de novo kidney grafts and undergone a therapeutic drug monitoring of Tac by morning C0 monitoring during early (1 to 90 days) and late (over 90 days) PT phases. The genomic DNA was extracted from peripheral blood mononuclear cells using a salting-out procedure. CYP3A4 promoter (rs2740574; -392A>G) and CYP3A5 (rs776746; 6986A>G) SNP genotyping was analyzed using PCR-RFLP. Results: Fifty-two patients were enrolled in the study. During the early PT phase, the CYP3A5 polymorphism but not that of CYP3A4, correlates significantly with Tac dose-normaliz...

19 April 2016 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
NFN Ben Fredj
N Ben Fredj
RGR Gam
R Gam
EKE Kerkni
E Kerkni
ACA Chaabane
A Chaabane
ZCZ Chadly
Z Chadly
KAKarim Aouam
Karim Aouam

9 July 2010 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
NFNadia Ben Fredj
Nadia Ben Fredj
KAKarim Aouam
Karim Aouam
ACAmel Chaabane
Amel Chaabane
ATAdnene Toumi
Adnene Toumi
FRFoued Ben Rhomdhane
Foued Ben Rhomdhane
MCMohamed Chakroun
Mohamed Chakroun
Click on the article title to read more.